Extended Data Fig. 4: No differences in the transcriptomic profile between MDM-1 identified in Trem2−/−5xFAD and Trem2+/+5xFAD and anti-PD-L1 or IgG2b treated mice. | Nature Aging

Extended Data Fig. 4: No differences in the transcriptomic profile between MDM-1 identified in Trem2−/−5xFAD and Trem2+/+5xFAD and anti-PD-L1 or IgG2b treated mice.

From: Alzheimer’s disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis

Extended Data Fig. 4

(a) FACS gating strategy for enriching monocyte-derived macrophages (MDM) from the brains of 7-9-month-old Trem2+/+5xFAD and Trem2−/−5xFAD mice, 14 days following injection of anti-PD-L1 or IgG2b. (b) A cumulative bar graphs of individual samples showing the percentage of each cell subpopulation out of all total non-microglial cells collected. (c) A volcano plot showing differentially expressed genes between MDM-1 and DAM, according to MARS-seq data corresponding to Fig. 4. (d) A scatter plot comparing the gene expression profile (log2) of MDM-1 cells collected from the brains of Trem2+/+5xFAD mice (83 cells) and Trem2−/−5xFAD mice (174 cells). (e) A scatter plot comparing the gene expression profile (log2) of MDM-1 cells collected from the brains of mice treated with anti-PD-L1 (83 cells) or IgG2b (102 cells). In figures (c-e) differential gene expression analysis was performed by Mann-Whitney U test with false-discovery rate (FDR) correction.

Back to article page